Vertex Pharmaceuticals

YTD

ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.

CEO

Reshma Kewalramani

CEOReshma Kewalramani

Employees

6,100

Employees6,100

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

1989

Founded1989

Employees

6,100

Employees6,100

VRTX Key Statistics

Market cap

100.54B

Market cap100.54B

Price-Earnings ratio

27.81

Price-Earnings ratio27.81

Dividend yield

—

Dividend yield—

Average volume

1.61M

Average volume1.61M

High today

$396.80

High today$396.80

Low today

$388.00

Low today$388.00

Open price

$389.53

Open price$389.53

Volume

1.52M

Volume1.52M

52 Week high

$519.88

52 Week high$519.88

52 Week low

$362.50

52 Week low$362.50

VRTX News

TipRanks 3d

Vertex Pharmaceuticals: Strong Prescription Growth and Strategic Initiatives Bolster Buy Rating

Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Vertex Pharmaceuticals. The associated price target remains the same with $530.00. Ele...

Simply Wall St 5d

Can Vertex Stock Bounce Back After 17% Drop and Promising Gene Therapy Results?

Advertisement Thinking About Vertex Pharmaceuticals Stock? Here’s What You Need to Know If you’ve been watching Vertex Pharmaceuticals lately, you’re definite...

Analyst ratings

61%

of 33 ratings

Buy

60.6%

Hold

36.4%

Sell

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.